Functional testosterone: Biochemical assessment of hypogonadism in men – Report from a multidisciplinary workshop hosted by the Ontario Society of Clinical Chemists

References

• Araujo A B, O'Donnell A B, Brambilla D J, Simpson W B, Longcope C, Matsumoto A M, McKinlay J B. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004; 89: 5920–5926
   PubMed Web of Science ®Google Scholar
• Tariq S H, Haren M T, Kim M J, Morley J E. Andropause: Is the emperor wearing any clothes?. Rev Endo Metab Dis 2005; 6: 77–84
   PubMedGoogle Scholar
• Tremblay R R, Gagne J M. Can we get away from serum total testosterone in the diagnosis of andropause?. The Aging Male 2005; 8: 147–150
   PubMedGoogle Scholar
• Morales A. Andropause (or symptomatic late-onset hypogonadism): facts, fiction and controversies. The Aging Male 2004; 7: 1–7
   PubMedGoogle Scholar
• Morales A, Buvat J, Gooren L J, Guay A T, Kaufman J M, Tan H M, Torres L O. Endocrine aspects of sexual dysfunction in men. J Sexual Medicine 2004; 1: 69–81
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu C W. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006; 27: 135–137
   PubMed Web of Science ®Google Scholar
• Bain J. Andropause: Testosterone replacement therapy for aging men. Can Fam Physician 2001; 47: 91–97
   PubMedGoogle Scholar
• Isidori A M, Lenzi A. Risk factors for androgen decline in older males: Lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005; 28(Suppl to no. 3)14–22
   PubMedGoogle Scholar
• Longcope C, Feldman H A, McKinlay J B, Araujo A B. Diet and sex hormone binding globulin. J Clin Endocrinol Metab 2000; 85: 293–296
   PubMed Web of Science ®Google Scholar
• Diver M J. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 2006; 43: 3–12
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Reviews 2005; 26(6)833–876
   PubMed Web of Science ®Google Scholar
• Allan C A, McLachlan R I. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol 2004; 60: 653–670
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman H A, McKinlay J B, Longcope C. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991; 73: 1016–1025
   PubMed Web of Science ®Google Scholar
• Diver M J, Imtiaz K E, Ahmad A M, Vora J P, Fraser W D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol 2003; 58: 710–717
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Bremner W. Editorial: Serum testosterone assays-accuracy matters. J Clin Endocrinol Metab 2004; 89: 520–524
   PubMed Web of Science ®Google Scholar
• Morley J E, Ping P, Perry H M, (III). Evaluation of assays available to measure free testosterone. Metabolism 2002; 51: 554–559
   PubMed Web of Science ®Google Scholar
• Rosner W, Auchus R J, Azziz R, Sluss P M, Raff H. POSITION STATEMENT: Utility, limitations, and pitfalls in measuring testosterone: An endocrine society position statement. J Clin Endocrinol Metab 2007; 92: 405–413
   PubMed Web of Science ®Google Scholar
• Gheorghiu I, Moshyk A, Lepage R, Ahnadi C E, Grant A M. When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?. Clin Biochem 2005; 38: 813–818
   PubMed Web of Science ®Google Scholar
• Lepage R. Measurement of testosterone and its sub-fractions in Canada. Clin Biochem 2006; 39: 97–108
   PubMed Web of Science ®Google Scholar
• Morris P D, Malkin C J, Channer K S, Jones T H. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol 2004; 151: 241–249
   PubMed Web of Science ®Google Scholar
• Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001; 86: 2903
   PubMed Web of Science ®Google Scholar
• Taieb J, Mathian B, Millot F, Patricot M C, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 Immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women and children. Clin Chem 2003; 49: 1381–1395
   PubMed Web of Science ®Google Scholar
• Wang C, Catlin D H, Demers L M, Starcevic B, Swerdloff R S. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectroscopy. J Clin Endocrinol Metab 2004; 89: 534–543
   PubMed Web of Science ®Google Scholar
• Emadi-Konjin P, Bain J, Bromberg I L. Evaluation of an algorithm for calculation of serum “bioavailable” testosterone (BAT). Clin Biochem 2003; 36: 591–596
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Berlin J A, Hannoush P. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–2677
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Berman N, Hull L, Swerdloff R S. Long-term testosterone gel (Androgel) treatment etc. J Clin Endocrinol Metab 2004; 89: 2085–2098
   PubMed Web of Science ®Google Scholar
• Kelleher S, Conway A J, Handelsman D J. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813–3817
   PubMed Web of Science ®Google Scholar
• Malkin C J, Pugh P J, Jones R D, Jones T H, Channer K S. Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability. J Endocrinol 2003; 178: 373–380
   PubMed Web of Science ®Google Scholar
• Black A M, Day A G, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?. BJU International 2004; 94: 1066–1070
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham G R, Hayes F J, Matsumoto A M, Snyder P J, Swerdloff R S, Montori V M. Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010
   PubMed Web of Science ®Google Scholar
• Shames D, Gassman A, Handelsman H. COMMENTARY: Guideline for male testosterone therapy: A regulatory perspective. J Clin Endocrinol Metab 2007; 92(2)414–415
   PubMedGoogle Scholar
• Haren M, Chapman I, Coates P, Morley J, Wittert G. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age and Aging 2005; 34: 125–130
   PubMed Web of Science ®Google Scholar